Trial Search Results

Cyclosporine in Treating Patients With Recurrent or Refractory Angioimmunoblastic T-Cell Lymphoma

RATIONALE: Cyclosporine may help the immune system slow the growth of angioimmunoblastic T-cell lymphoma.

PURPOSE: This phase II trial is studying how well cyclosporine works in treating patients with recurrent or refractory angioimmunoblastic T-cell lymphoma.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Eastern Cooperative Oncology Group

Collaborator: National Cancer Institute (NCI)

Stanford Investigator(s):

Intervention(s):

  • Drug: cyclosporine

Phase:

Phase 2

Eligibility


Inclusion Criteria:

   - Diagnosis of angioimmunoblastic T-cell lymphoma (recurrent or refractory) based on
   histologic examination.

   - At least one objective measurable or evaluable disease parameter.

   - Have failed at least one type of treatment: chemotherapy, auto-transplant, or steroid
   treatment. Patients may not receive concurrent chemotherapy.

   - Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.

   - Adequate renal function as indicated by creatinine <= 1.5 the upper limit of normal
   (ULN).

   - Adequate liver function as indicated by alkaline phosphatase, Aspartate
   Aminotransferase (AST), and Alanine Aminotransferase (ALT) <= 2x the upper limit of
   normal.

   - Total bilirubin <= 2x the upper limit of normal.

   - Age 18 or older.

Exclusion Criteria:

   - Prior cyclosporine or Tacrolimus (FK506).

   - Prior allogeneic transplant.

   - Evidence of active infection.

   - Congestive heart failure, kidney failure, liver failure, or other severe
   co-morbidities.

   - Evidence of active neurological impairment.

   - Previous history of hypersensitivity to cyclosporine and/or Cremorphor EL
   (polyoxyethylated oil).

   - History of other malignancies (other than cured carcinomas in situ of the cervix or
   basal cell carcinoma of the skin).

   - pregnant or breastfeeding women.

   - Human immunodeficiency virus (HIV) positive.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Cancer Clinical Trials Office
6504987061
Not Recruiting